Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Crit Care
2022 Sep 14;261:278. doi: 10.1186/s13054-022-04153-3.
Show Gene links
Show Anatomy links
Plasma SARS-CoV-2 nucleocapsid antigen levels are associated with progression to severe disease in hospitalized COVID-19.
Wick KD
,
Leligdowicz A
,
Willmore A
,
Carrillo SA
,
Ghale R
,
Jauregui A
,
Chak SS
,
Nguyen V
,
Lee D
,
Jones C
,
Dewar R
,
Lane HC
,
Kangelaris KN
,
Hendrickson CM
,
Liu KD
,
Sinha P
,
Erle DJ
,
Langelier CR
,
Krummell MF
,
Woodruff PG
,
Calfee CS
,
Matthay MA
,
COMET Consortium
.
???displayArticle.abstract???
BACKGROUND: Studies quantifying SARS-CoV-2 have focused on upper respiratory tract or plasma viral RNA with inconsistent association with clinical outcomes. The association between plasma viral antigen levels and clinical outcomes has not been previously studied. Our aim was to investigate the relationship between plasma SARS-CoV-2 nucleocapsid antigen (N-antigen) concentration and both markers of host response and clinical outcomes.
METHODS: SARS-CoV-2 N-antigen concentrations were measured in the first study plasma sample (D0), collected within 72 h of hospital admission, from 256 subjects admitted between March 2020 and August 2021 in a prospective observational cohort of hospitalized patients with COVID-19. The rank correlations between plasma N-antigen and plasma biomarkers of tissue damage, coagulation, and inflammation were assessed. Multiple ordinal regression was used to test the association between enrollment N-antigen plasma concentration and the primary outcome of clinical deterioration at one week as measured by a modified World Health Organization (WHO) ordinal scale. Multiple logistic regression was used to test the association between enrollment plasma N-antigen concentration and the secondary outcomes of ICU admission, mechanical ventilation at 28 days, and death at 28 days. The prognostic discrimination of an externally derived "high antigen" cutoff of N-antigen ≥ 1000 pg/mL was also tested.
RESULTS: N-antigen on D0 was detectable in 84% of study participants. Plasma N-antigen levels significantly correlated with RAGE (r = 0.61), IL-10 (r = 0.59), and IP-10 (r = 0.59, adjusted p = 0.01 for all correlations). For the primary outcome of clinical status at one week, each 500 pg/mL increase in plasma N-antigen level was associated with an adjusted OR of 1.05 (95% CI 1.03-1.08) for worse WHO ordinal status. D0 plasma N-antigen ≥ 1000 pg/mL was 77% sensitive and 59% specific (AUROC 0.68) with a positive predictive value of 23% and a negative predictive value of 93% for a worse WHO ordinal scale at day 7 compared to baseline. D0 N-antigen concentration was independently associated with ICU admission and 28-day mechanical ventilation, but not with death at 28 days.
CONCLUSIONS: Plasma N-antigen levels are readily measured and provide important insight into the pathogenesis and prognosis of COVID-19. The measurement of N-antigen levels early in-hospital course may improve risk stratification, especially for identifying patients who are unlikely to progress to severe disease.
???displayArticle.pubmedLink???
36104754
???displayArticle.link???Crit Care ???displayArticle.grants???[+]
Abers,
An immune-based biomarker signature is associated with mortality in COVID-19 patients.
2021, Pubmed
Abers,
An immune-based biomarker signature is associated with mortality in COVID-19 patients.
2021,
Pubmed
Ahava,
Detection of SARS-CoV-2 nucleocapsid antigen from serum can aid in timing of COVID-19 infection.
2022,
Pubmed
Almansa,
N-antigenemia detection by a rapid lateral flow test predicts 90-day mortality in COVID-19: A prospective cohort study.
2022,
Pubmed
Andersson,
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus.
2020,
Pubmed
Angus,
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
2020,
Pubmed
Berastegui-Cabrera,
SARS-CoV-2 RNAemia is associated with severe chronic underlying diseases but not with nasopharyngeal viral load.
2021,
Pubmed
Bermejo-Martin,
Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19.
2020,
Pubmed
Boyapati,
Baseline Severe Acute Respiratory Syndrome Viral Load Is Associated With Coronavirus Disease 2019 Severity and Clinical Outcomes: Post Hoc Analyses of a Phase 2/3 Trial.
2021,
Pubmed
Brasen,
Daily monitoring of viral load measured as SARS-CoV-2 antigen and RNA in blood, IL-6, CRP and complement C3d predicts outcome in patients hospitalized with COVID-19.
2021,
Pubmed
Brunet-Ratnasingham,
Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality.
2021,
Pubmed
Calvet,
Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission.
2022,
Pubmed
Chen,
Dynamics of Blood Viral Load Is Strongly Associated with Clinical Outcomes in Coronavirus Disease 2019 (COVID-19) Patients: A Prospective Cohort Study.
2021,
Pubmed
Chen,
Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019.
2020,
Pubmed
Cornelius,
Tobacco Product Use Among Adults - United States, 2019.
2020,
Pubmed
Deng,
High Performance of SARS-Cov-2N Protein Antigen Chemiluminescence Immunoassay as Frontline Testing for Acute Phase COVID-19 Diagnosis: A Retrospective Cohort Study.
2021,
Pubmed
Fajnzylber,
SARS-CoV-2 viral load is associated with increased disease severity and mortality.
2020,
Pubmed
Fukuda,
Utility of SpO2/FiO2 ratio for acute hypoxemic respiratory failure with bilateral opacities in the ICU.
2021,
Pubmed
Hagman,
Severe Acute Respiratory Syndrome Coronavirus 2 RNA in Serum as Predictor of Severe Outcome in Coronavirus Disease 2019: A Retrospective Cohort Study.
2021,
Pubmed
Heinrich,
SARS-CoV-2 Blood RNA Load Predicts Outcome in Critically Ill COVID-19 Patients.
2021,
Pubmed
Herold,
Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19.
2020,
Pubmed
Huang,
Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection.
2021,
Pubmed
Hue,
Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome.
2020,
Pubmed
IMPACC Manuscript Writing Team,
Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study.
2021,
Pubmed
Islam,
Elevated Interleukin-10 Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired Anti-Inflammatory Action?
2021,
Pubmed
Jacobs,
Severe Acute Respiratory Syndrome Coronavirus 2 Viremia Is Associated With Coronavirus Disease 2019 Severity and Predicts Clinical Outcomes.
2022,
Pubmed
Junqueira,
FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation.
2022,
Pubmed
Kawasuji,
SARS-CoV-2 RNAemia with a higher nasopharyngeal viral load is strongly associated with disease severity and mortality in patients with COVID-19.
2022,
Pubmed
Knudtzen,
SARS-CoV-2 viral load as a predictor for disease severity in outpatients and hospitalised patients with COVID-19: A prospective cohort study.
2021,
Pubmed
Le Hingrat,
Corrigendum to 'detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives'.
2021,
Pubmed
Leisman,
Alveolar, Endothelial, and Organ Injury Marker Dynamics in Severe COVID-19.
2022,
Pubmed
Leisman,
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.
2020,
Pubmed
Lundgren,
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.
2022,
Pubmed
Lundgren,
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.
2021,
Pubmed
Magleby,
Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease 2019.
2021,
Pubmed
Martin-Vicente,
Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients.
2022,
Pubmed
Meizlish,
A neutrophil activation signature predicts critical illness and mortality in COVID-19.
2021,
Pubmed
Mick,
Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses.
2020,
Pubmed
Nijhuis,
Low prevalence of SARS-CoV-2 in plasma of COVID-19 patients presenting to the emergency department.
2020,
Pubmed
Ogata,
Ultra-Sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease.
2020,
Pubmed
Olea,
SARS-CoV-2 N-antigenemia in critically ill adult COVID-19 patients: Frequency and association with inflammatory and tissue-damage biomarkers.
2022,
Pubmed
Prebensen,
Severe Acute Respiratory Syndrome Coronavirus 2 RNA in Plasma Is Associated With Intensive Care Unit Admission and Mortality in Patients Hospitalized With Coronavirus Disease 2019.
2021,
Pubmed
Salto-Alejandre,
SARS-CoV-2 viral load in nasopharyngeal swabs is not an independent predictor of unfavorable outcome.
2021,
Pubmed
Shan,
N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection.
2021,
Pubmed
Sigal,
Measurement of Severe Acute Respiratory Syndrome Coronavirus 2 Antigens in Plasma of Pediatric Patients With Acute Coronavirus Disease 2019 or Multisystem Inflammatory Syndrome in Children Using an Ultrasensitive and Quantitative Immunoassay.
2022,
Pubmed
Tang,
Quantitative assessment of SARS-CoV-2 RNAemia and outcome in patients with coronavirus disease 2019.
2021,
Pubmed
Thudium,
Early Laboratory Diagnosis of COVID-19 by Antigen Detection in Blood Samples of the SARS-CoV-2 Nucleocapsid Protein.
2021,
Pubmed
Veyer,
Highly Sensitive Quantification of Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Sheds Light on its Potential Clinical Value.
2021,
Pubmed
Wang,
SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19.
2021,
Pubmed
Wick,
RAGE has potential pathogenetic and prognostic value in nonintubated hospitalized patients with COVID-19.
2022,
Pubmed
Yamakawa,
Proteolytic release of the receptor for advanced glycation end products from in vitro and in situ alveolar epithelial cells.
2011,
Pubmed
de la Calle,
Impact of viral load at admission on the development of respiratory failure in hospitalized patients with SARS-CoV-2 infection.
2021,
Pubmed